None
Quote | Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX)
Last: | $3.82 |
---|---|
Change Percent: | 0.0% |
Open: | $4.05 |
Close: | $3.82 |
High: | $4.29 |
Low: | $3.79 |
Volume: | 45,132 |
Last Trade Date Time: | 10/13/2023 03:00:00 am |
News | Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX)
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned next Study In Nonsense Mutation Alport Syndrome Signed Glob...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...
Message Board Posts | Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX)
Subject | By | Source | When |
---|---|---|---|
$ELOX: Told-ya-all-so, it it's movin' AGAIN!!! (Wildest day | Invest-in-America | investorshub | 07/11/2023 7:17:17 PM |
$ELOX: Easiest profit day-trade in the history of | Invest-in-America | investorshub | 07/11/2023 3:37:09 PM |
$ELOX halted | Monksdream | investorshub | 07/11/2023 1:40:05 PM |
$ELOX - Up 14% Pre-Market/ Current Price $4.69 | AJ Freely | investorshub | 07/11/2023 11:59:58 AM |
short squeeze signal | Fofo812 | investorshub | 07/10/2023 7:55:25 AM |
News, Short Squeeze, Breakout and More Instantly...
Eloxx Pharmaceuticals Inc. Company Name:
ELOX Stock Symbol:
NASDAQ Market:
Eloxx Pharmaceuticals Inc. Website:
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned next Study In Nonsense Mutation Alport Syndrome Signed Glob...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon ...